One story, three bylines
Read The Guardian, The Mirror and The Independent next to each other and you find the same material three times. Each has the same two patients, Jonathan Walden (“I go hunting; I can go fishing”) and Shari St Germain on the treadmill. Each quotes Dr Anastasia Zekeridou on “the degree of improvement we saw in some patients” and Dr Sean Pittock on “tremendous hope”. The background lines match word for word too: “SPS affects an estimated 8,000 people worldwide”ChurnalismChurnalism is a press release, wire feed, or one outlet's unsourced reporting republished under several bylines and read by the public as independent confirmation. [3] [4], and the study “could now lead to larger trials in people with SPS” [3] [4]. The Guardian and The Independent also share the quote from the charity Anthony Nolan [2] [4].
None of the articles says where this shared package came from. The shape suggests a single institutional release reworked by each outlet, but none of the three says so, and a reader can’t tell. That is what churnalism does to a reader: three outlets look like three confirmations, when they may be one account told three times. One sign to watch for is identical patient anecdotes and statistics turning up under different bylines on the same afternoon.
The headline drops the hedge
The Guardian’s own first paragraph is careful. It says doctors have made “a potentially significant breakthrough” [2]. The headline above it removes that qualifier and announces a “Medical breakthrough”Modal deletionModal deletion is dropping a hedge word like 'could' from a headline, turning a hypothesis the article's own body still calls conditional into a present-tense fact. [2]. This is modal deletion. A reader who only skims, or only sees the headline in a feed, gets a settled finding. The article’s own writer called it a possibility.
The Independent does something similar with numbers. Its headline says the treatment “sees patients walk again”Headline asserts, body hedgesThe mother pattern behind scare quotes, modal deletion, and the commitment-free statement: a headline states a claim as settled fact while the article underneath it quietly hedges, denies, or contradicts it. [4]. Its body says the treatment “allowed two trial subjects to recover essential everyday capabilities” [4]. “Patients” in a headline sounds like the trial population. The body is describing two people, the same two every outlet quotes. This is headline asserts, body hedges: the claim on top is broader than anything underneath it supports. To spot it, look for the number in the body that the headline’s plural never states.
Stronger in the outlets’ voice than in the doctors’
The researchers quoted are measured. Zekeridou says improvement came “in some patients” and calls the results “early”, adding that “the key question now is whether those improvements will be sustained over time” [2]. Pittock says “There is still much we need to learn” [2].
In their own narration, the outlets drop those limits. The Guardian writes that the treatment “has prompted dramatic improvements in people living with SPSCertainty upgradeA certainty upgrade restates a source's claim in the outlet's own voice more firmly than the source made it: a hedge, a limit or a caveat in the original disappears in the retelling.” [2]. Zekeridou’s “some patients” has become people with the disease in general. The Independent says the therapy “has shown significant success” [4]. The Mirror goes furthest: “a gene therapy which corrects faulty DNA has been shown to reverse stiffness” [3]. This is a certainty upgrade. The caveat stays in the quote, often near the bottom (The Mirror holds Zekeridou’s “key question” line for its final sentence [3]), and the outlet’s voice carries the firmer version. A reader should treat the quoted scientist’s wording as the ceiling on any claim.
The Mirror’s description also contradicts itself. It calls the treatment a therapy that “corrects faulty DNA” [3]. A few paragraphs later, it correctly describes T cells being harvested and “genetically engineering them to be able to recognise and kill the cells in the body which cause disease” [3]. CAR-T modifies immune cells. It does not repair the patient’s DNA. Its headline offers “may have found a cure” [3]. Nobody quoted in the article uses the word cure.
A journal named, nothing shown from it
Each outlet anchors the story to the journal. The Guardian says the results were “published in medical journal Jama Neurology”Proof by invocationProof by invocation cites a report, a study or unnamed experts as having shown something, without giving a single figure, name or finding from them, so the reader can only take the conclusion on trust. [2]. The Mirror and The Independent say “The new study, published in Jama Neurology” [3] [4]. The journal’s name stands in for evidence that none of the articles reproduces. None says how many people were actually treated. The Mirror says only that the trial “sought to enrol 27 participants” [3], which is a target, not a count. None gives an outcome measure, how many patients improved or how long they were followed. This is proof by invocation. The name of a peer-reviewed journal makes the result feel checked, while the reader gets nothing to check it against.
What’s missing: the risk
Walden tells The Independent he almost turned the trial down, but decided he was “better off going ahead and taking the risk” [4]. None of the three outlets explains what that risk was. None mentions side effects at all.
ScienceNews, covering a separate trial of a different CAR-T product, shows that this information is easy to report. It says “the most common serious side effect” was “a low white blood cell count” and that scientists “don’t yet know whether patients will need multiple infusions” [1]. It also gives figures: 26 patients, and “eight of 12 people who had relied on a walking aid no longer needed one” [1]. Its own framing has some lift too. The headline says the drug “restores mobility” [1], while the body says the strategy “seemed successful” [1]. Still, a reader comes away with numbers, a named company (Kyverna Therapeutics) and a regulatory timeline. The UK reports give none of these.
The Independent ends with Anthony Nolan’s point that “we must consider how treatments like this can be delivered in practice” [4], meaning workforce, infrastructure and resources. That is the only place where cost or access to an expensive cell therapy comes up, and it appears only as a charity’s closing remark.
Céline Dion appears in all three UK headlines. She is not reported as having taken part in the trial or received this therapy. The Mirror spends paragraphs on her as the “Queen of Power Ballads” and on her documentary [3]. The celebrity frame decides how big the story looks. The data does not.
What a reader would need instead
6 checks to run on the next story like this one.
-
How many patients were actually treated in the Mayo trial, how many improved, by how much, and for how long they were followed, taken from the JAMA Neurology paper itself.
-
Its side effects and serious adverse events, and what “the risk” Walden weighed actually involved.
Gap in the coverage
-
Whether the trial had a control group, and what phase it was.
Gap in the coverage
-
Who funded the trial, and whether a company is developing the product.
Gap in the coverage
-
Where the regulatory process stands. ScienceNews notes that no FDA-approved treatment for SPS exists [1]. In the UK, that would mean asking whether the MHRA or NICE has assessed CAR-T for autoimmune use.
Gap in the coverage
-
A clear line between what the researchers said and what the outlet concluded, so that “some patients” and “early results” stay that way.
